Home » Consulting Services » Business and Data Analysis »

Business and Data Analysis

Business and Data Analysis

PHSI uses its vast industry experience along with analysis techniques and financial modeling to solve your toughest business problems. We analyze your situation from different points of view and identify opportunities or potential problems before they occur. Prior to your investment in a new business process or program, let PHSI model and assess its impact on your financial results.

View our case studies related to business and data analysis:

340B Compliance Review

Accounting Firm Required Pharmacy Expertise

Client Selects Copay Reduction Program

Determining Competitive Market Landscape

Drug Resources Made Available via Manufacturer’s Website

Generic Competition Studied to Determine Effects on Brand Drug

Generic Market Forecasting

Industry Monitoring, Research, & Analysis Used as a Vital Decision Resource

Manufacturer Seeks Pre-Launch Rebate Level Forecasting

Medicare PDP Develops Community Pharmacy MTM Program

PBM Contract Variance Analysis

PBM Positions Itself for Increased Rebate Yield

PHSI Helps PBM Develop a Pharmacy Network Contracting Strategy

PHSI Helps Supermarket Chain Move Toward Providing Pharmaceutical Care

Proactive Response to Loss of Brand Patent Protection

Rebate Contracting Consolidation Process Directed by PHSI

Research Updates Brand Designation in Drug Databases

Seasonal-Use Product Reimbursement Trend Analysis

Specialty Drug Reimbursement by Pharmacy Type

U&C Pricing Strategy Critical for Chain Expansion

September 2019 Question of the Month

Who will be the slowest to adopt the electronic real-time benefit check?

Physicians: 53.8%

PBMs: 30.8%

EMRs: 15.4%

Surescripts: 0%

August 2019 Question of the Month

If the NADAC survey of pharmacy costs becomes mandatory, how will this impact the NADAC and Medicaid pharmacy reimbursement?

NADAC would decrease, resulting in lower Medicaid reimbursements to pharmacies: 88%

NADAC would not change and Medicaid reimbursements would remain the same: 12%

NADAC would increase, resulting in higher Medicaid reimbursements to pharmacies: 0%

July 2019 Question of the Month

What percent of new drugs in the next 5 years will use alternative payment models like subscription plans or multi-year payment plans?

0%: 0%

1% to 5%: 82%

5% to 10%: 9%

10% to 20%: 9%

20% to 30%: 0%